CN116918963A - Total nutrient formula food applicable to pancreatitis patients and having special medical application - Google Patents
Total nutrient formula food applicable to pancreatitis patients and having special medical application Download PDFInfo
- Publication number
- CN116918963A CN116918963A CN202310823274.XA CN202310823274A CN116918963A CN 116918963 A CN116918963 A CN 116918963A CN 202310823274 A CN202310823274 A CN 202310823274A CN 116918963 A CN116918963 A CN 116918963A
- Authority
- CN
- China
- Prior art keywords
- oil
- protein
- component
- carbohydrate
- total nutrient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 72
- 206010033645 Pancreatitis Diseases 0.000 title claims abstract description 66
- 235000013305 food Nutrition 0.000 title claims abstract description 53
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 81
- 235000004252 protein component Nutrition 0.000 claims abstract description 76
- 235000016709 nutrition Nutrition 0.000 claims abstract description 66
- 235000018102 proteins Nutrition 0.000 claims abstract description 48
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 48
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 48
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 43
- 239000011707 mineral Substances 0.000 claims abstract description 43
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims abstract description 42
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 42
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 42
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 42
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 41
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 41
- 108010053210 Phycocyanin Proteins 0.000 claims abstract description 41
- 229940088594 vitamin Drugs 0.000 claims abstract description 41
- 229930003231 vitamin Natural products 0.000 claims abstract description 41
- 235000013343 vitamin Nutrition 0.000 claims abstract description 41
- 239000011782 vitamin Substances 0.000 claims abstract description 41
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 40
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 40
- 235000021119 whey protein Nutrition 0.000 claims abstract description 40
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 239000003921 oil Substances 0.000 claims description 142
- 235000019198 oils Nutrition 0.000 claims description 142
- 241000195493 Cryptophyta Species 0.000 claims description 37
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 36
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims description 35
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 35
- 235000019498 Walnut oil Nutrition 0.000 claims description 35
- 239000001335 perilla frutescens leaf extract Substances 0.000 claims description 35
- 239000008170 walnut oil Substances 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 17
- -1 compound vitamin Chemical class 0.000 claims description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 4
- 240000008620 Fagopyrum esculentum Species 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 240000000950 Hippophae rhamnoides Species 0.000 claims 1
- 244000170916 Paeonia officinalis Species 0.000 claims 1
- 230000035764 nutrition Effects 0.000 abstract description 46
- 241000219051 Fagopyrum Species 0.000 abstract description 40
- 239000000306 component Substances 0.000 description 120
- 235000019197 fats Nutrition 0.000 description 93
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 39
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 38
- 230000000052 comparative effect Effects 0.000 description 36
- 241000229143 Hippophae Species 0.000 description 34
- 241000736199 Paeonia Species 0.000 description 34
- 239000002994 raw material Substances 0.000 description 32
- 150000003722 vitamin derivatives Chemical class 0.000 description 31
- 210000002966 serum Anatomy 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 150000003626 triacylglycerols Chemical class 0.000 description 13
- 102000004882 Lipase Human genes 0.000 description 10
- 108090001060 Lipase Proteins 0.000 description 10
- 239000004367 Lipase Substances 0.000 description 10
- 229940040461 lipase Drugs 0.000 description 10
- 235000019421 lipase Nutrition 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 150000004665 fatty acids Chemical class 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 9
- 206010033647 Pancreatitis acute Diseases 0.000 description 8
- 201000003229 acute pancreatitis Diseases 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000003814 Interleukin-10 Human genes 0.000 description 7
- 108090000174 Interleukin-10 Proteins 0.000 description 7
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 229940076144 interleukin-10 Drugs 0.000 description 7
- 229940100601 interleukin-6 Drugs 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 239000004382 Amylase Substances 0.000 description 4
- 102000013142 Amylases Human genes 0.000 description 4
- 108010065511 Amylases Proteins 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical class CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 235000019418 amylase Nutrition 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 235000019149 tocopherols Nutrition 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 239000013022 formulation composition Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940057917 medium chain triglycerides Drugs 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 229940068065 phytosterols Drugs 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000015163 Biliary Tract disease Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033627 Pancreatic injury Diseases 0.000 description 1
- 241000269435 Rana <genus> Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000008383 multiple organ dysfunction Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/195—Proteins from microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pediatric Medicine (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a total nutrient formula food applicable to special medical use of pancreatitis patients, and belongs to the technical field of special medical use formulas. The invention relates to a total nutrient formula food suitable for special medical use of pancreatitis patients, which comprises, by mass, 10% -20% of fat components, 15% -25% of protein components, 60% -70% of carbohydrate components, 0.5% -1% of compound vitamins and 1% -5% of compound minerals; wherein: the fat component consists of diglyceride and nutritional oil; the protein component consists of buckwheat protein, phycocyanin and whey protein; the carbohydrate consists of maltodextrin and beta-glucan. The full-nutrition formula food provided by the invention provides sufficient nutrition support for HTG-AP patients through scientific and reasonable matching of the proportion of each nutrient.
Description
Technical Field
The invention belongs to the technical field of special medical use formulas, and particularly relates to a full-nutrition formula food applicable to special medical use of pancreatitis patients.
Background
Common causes of acute pancreatitis are biliary tract diseases, alcoholism, and high-fat diet. With the improvement of living standard of residents and the change of dietary structure, the prevalence of hyperlipidemic acute pancreatitis (HTG-AP) is on the rise, and becomes the second largest constitution of acute pancreatitis. High levels of triglycerides in serum accumulate in the pancreas, and pancreatic lipase breaks down triglycerides into a large amount of free fatty acids, which, if at too high concentrations, not only directly act on pancreatic acini, but also promote calcium overload and endoplasmic reticulum oxidative stress, thereby causing microcirculation disturbance and triggering inflammation. Thus, reducing blood lipids is critical for preventing and treating HTG-AP. Currently, most of nutritional preparations or oral diets for patients with acute pancreatitis reduce blood lipid by reducing lipid intake, and thus malnutrition is easily caused for a long period of time.
Diglyceride is a trace component of natural vegetable oil and fat metabolism endogenous intermediate product in human body, and is hydrolyzed into monoglyceride and free fatty acid by pancreatic lipase in duodenum and small intestine, the free fatty acid is mainly transported to liver and released in energy form by beta oxidation, monoglyceride is not easy to resynthesize triglyceride, triglyceride content entering blood is correspondingly reduced, and blood fat is reduced. Therefore, the diglyceride is used for partially replacing triglyceride in the diet, so that not only can the blood fat be effectively reduced, but also the essential nutrients can be provided, and the HTG-AP patient can be helped to recover as soon as possible.
A pancreatitis total nutrient formula food belongs to one of special medical purpose formula foods. Currently, fat formulations for HTG-AP are mainly focused on medium chain triglycerides, and the use of diglycerides in this regard is omitted. A composition suitable for the recovery phase of patients suffering from hyperlipidemic acute pancreatitis and a process for its preparation are disclosed in patent CN113615832A, which emphasizes the hypolipidemic effect of medium-chain triglycerides in the fat component, but does not involve diglycerides. The composition of the fat component is optimized through the compounding of diglyceride and high-quality grease, and the fat component and nutrients such as protein, carbohydrate and the like are used cooperatively, so that the blood fat of a patient can be reduced, and the real nutritional requirements of the patient can be met. At present, the research and development of the total nutrient formula food for the pancreatitis with hyperlipidemia in China is in the primary stage, and how to prepare the total nutrient formula food suitable for the pancreatitis patients with special medical application is a technical problem to be solved in the field.
Disclosure of Invention
In view of the deficiencies of the related art, the present invention provides a total nutritional formula for special medical uses in pancreatitis patients, including fat components, protein components, carbohydrate components, vitamins and minerals complexes. The special medical food provided by the invention has scientific and reasonable proportion of each nutrient, can provide sufficient nutritional support for HTG-AP patients, and has a certain effect on preventing and relieving HTG-AP.
In particular, the method comprises the steps of,
the invention provides a total nutrient formula food suitable for special medical use of pancreatitis patients, which comprises, by mass, 10% -20% of fat components, 15% -25% of protein components, 60% -70% of carbohydrate components, 0.5% -1% of compound vitamins and 1% -5% of compound minerals;
wherein: the fat component consists of diglyceride and nutritional oil; the protein component consists of buckwheat protein, phycocyanin and whey protein; the carbohydrate consists of maltodextrin and beta-glucan.
As an embodiment of the present invention, the specific content of the fat component may be selected from 10%, 13%, 15%, 20%.
As one embodiment of the invention, the specific content of the protein component can be selected from 15%, 18%, 20%, 23% and 25%.
As an embodiment of the present invention, the specific content of the carbohydrate module may be selected from 60%, 63%, 65%, 68%, 70%.
As one embodiment of the invention, the specific content of the compound vitamin is optionally 0.8%.
As one embodiment of the invention, the specific content of the composite mineral is 1.2%.
As one embodiment of the present invention, the fat component, protein component, carbohydrate component, multivitamin, complex mineral ratio is 15%, 20%, 63%, 0.8%, 1.2%, respectively.
As an embodiment of the present invention, the fat component comprises 50 to 70% by mass of diglyceride, and the nutritional oil is supplemented to 100%.
As an embodiment of the present invention, the fat component has a diglyceride content of 63% and a nutritional oil content of 37% by mass.
As an embodiment of the present invention, diglycerides refer to structural lipids in which one fatty acid in the triglyceride is substituted with a hydroxyl group, including 1, 3-diglycerides and 1, 2-diglycerides and fatty acids attached to the diglyceride backbone include, but are not limited to, stearic acid, palmitic acid, oleic acid, linoleic acid.
As an embodiment of the present invention, the nutritional oil includes perilla seed oil, peony seed oil, walnut oil, sea buckthorn oil and DHA algae oil.
As one embodiment of the invention, the nutritional oil composition comprises linoleic acid with a ratio of 10.86+/-0.01%, oleic acid with a ratio of 7.39+/-0.01% and omega-3 unsaturated fatty acid with a ratio of 13.93+/-0.01%.
As an embodiment of the invention, the fat component comprises, by mass, 50-70% of diglyceride, 10-15% of perilla seed oil, 8-12% of peony seed oil, 8-12% of walnut oil, 3-7% of sea buckthorn oil and 1-4% of DHA algae oil.
As one embodiment of the invention, the fat component comprises 63% of diglyceride, 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil by mass percent.
As one embodiment of the invention, the mass ratio of the buckwheat protein, the phycocyanin and the whey protein in the protein assembly is 1:1-3:1-3, preferably the ratio is 1:1:2.
As one embodiment of the invention, the mass ratio of maltodextrin to beta-glucan in the carbohydrate module is (8-12): 1, a step of; the specific ratio is 10:1.
As one embodiment of the invention, each 100g of food contains vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K and folic acid in the mass ratio of 1-3:4-6:1-3: 7-9:2-4:9-12: 1:2-4:1-3: 1 to 2; the preferred ratio is 2:5:1:8:2:12:1:3:3:2.
As one embodiment of the invention, each 100g of food contains minerals of calcium, sodium, potassium, magnesium, phosphorus, iron and zinc in the mass ratio of 18-22:18-22:28-32: 4-6:3-5:1-2: 1, a step of; the preferred ratio is 20:20:30:5:4:1:1.
As an embodiment of the invention, the food product is in a form including, but not limited to, powder and liquid forms.
As an embodiment of the present invention, the pancreatitis is hyperlipidemia pancreatitis.
Compared with the prior art, the invention has the following beneficial effects:
the key to preventing and alleviating HTG-AP is to reduce blood lipid and anti-inflammatory. The fat component adopts the form of diglyceride compound nutritional oil, wherein the nutritional oil comprises perilla seed oil, peony seed oil, walnut oil, sea buckthorn oil and DHA algae oil. Diglycerides are well-known safe (GRAS) food ingredients that differ entirely from the digestive pathways of triglycerides. The digestion products of the triglyceride are further synthesized into the triglyceride in intestinal epithelial cells and then enter the blood in the form of chylomicron or very low density lipoprotein, so that the blood fat is increased, the digestion products of the diglyceride are not easy to resynthesize the triglyceride, and the triglyceride is released in the form of energy, so that the triglyceride has remarkable blood fat reducing effect. In terms of fatty acid composition of the nutritional oil, omega-3 series of alpha-linolenic acid, DHA, EPA and omega-6 series of linoleic acid are added, wherein the omega-3 series can inhibit pro-inflammatory factors in vivo and weaken the degree of inflammatory reaction. Through scientific compounding of diglyceride and nutritional oil, the daily oil intake requirement of HTG-AP patients is met, and the compound preparation has a certain effect on prevention and alleviation of HTG-AP.
The invention selects buckwheat protein, phycocyanin and whey protein as protein sources. The buckwheat protein contains 18 rich amino acids, and 8 amino acids necessary for human body have reasonable composition and proper proportion, and have the function of inhibiting fat accumulation. Phycocyanin has excellent antioxidant and antiinflammatory activities, and can effectively inhibit various diseases caused by inflammation. Whey protein not only has a fast digestion rate in the intestinal tract, but also plays an important role in lipid metabolism and the like. The combination energy of the three high-quality proteins is complementary in function, the nutrition is more comprehensive, the nutrition requirement of HTG-AP patients is met, and the net nitrogen loss of pancreatitis patients in the acute phase is reduced.
The invention selects maltodextrin and beta-glucan as carbohydrate sources. Maltodextrin is easy to be digested and absorbed by human body, and can rapidly supply energy to meet the energy requirement of HTG-AP patients. In addition, the beta-glucan serving as dietary fiber has various active functions of enhancing immunity, regulating intestinal flora, reducing blood fat and the like, and is beneficial to HTG-AP patients.
The full-nutrition formula food for special medical purposes, provided by the invention, is suitable for pancreatitis patients, has scientific and reasonable proportion of each nutrient, and can provide sufficient nutrition support for HTG-AP patients.
Detailed Description
The invention is further illustrated below in connection with specific examples, which are given by way of illustration of detailed embodiments and operational steps of the invention, but the scope of the invention is not limited thereto.
In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention, but the present invention may be practiced in other ways other than those described herein, and persons skilled in the art will readily appreciate that the present invention is not limited to the specific embodiments disclosed below.
Further, reference herein to "one embodiment" or "an embodiment" means that a particular feature, structure, or characteristic can be included in at least one implementation of the invention. The appearances of the phrase "in one embodiment" in various places in the specification are not necessarily all referring to the same embodiment, nor are separate or alternative embodiments mutually exclusive of other embodiments.
The compositions of the following examples were prepared by the following methods:
and under the condition of room temperature, uniformly mixing the nutritional grease according to the mass ratio at the stirring speed of 90-120 rpm for 10-15 min, heating to 40-50 ℃ at the speed of 4 ℃/min, adding diglyceride, stirring for 20min, and stopping to obtain the fat component.
The fat component is dissolved in distilled water and stirred in a constant temperature water bath at 55 ℃ for 10 to 15 minutes.
Weighing buckwheat protein, phycocyanin and whey protein according to the mass ratio, stirring in distilled water in a constant-temperature water bath at 45 ℃ for 40-60 min to fully dissolve the buckwheat protein, the phycocyanin and the whey protein; weighing maltodextrin and beta-glucan according to the mass ratio, and stirring in distilled water in a constant-temperature water bath at 50 ℃ for 20-25 min to fully dissolve the maltodextrin and the beta-glucan; weighing the compound vitamin and the compound mineral according to the mass ratio, stirring in distilled water in a constant-temperature water bath at 45 ℃ for 30-40 min to fully dissolve the compound vitamin and the compound mineral.
Finally, mixing the fat component, the protein component and the carbohydrate component in the steps, performing a high-speed shearing machine at 15000-20000 rpm, and performing a mixing high-pressure homogenizer at 500-600 MPa to obtain the final product.
In the total nutrient formula food, the compound vitamin consists of vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K and folic acid according to the mass ratio of 2:5:1:8:2:12:1:3:3:2. The composite mineral consists of calcium, sodium, potassium, magnesium, phosphorus, iron and zinc according to the mass ratio of 20:20:30:5:4:1:1.
Example 1 (S1):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 15% fat component, 20% protein component, 63% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 63% of diglyceride and 37% of nutrition oil, the nutrition oil consists of 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil, the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin and beta-glucan in the carbohydrate is 10:1.
Example 2 (S2):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 10% fat component, 23% protein component, 65% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 63% of diglyceride and 37% of nutrition oil, the nutrition oil consists of 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil, the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin and beta-glucan in the carbohydrate is 10:1.
Example 3 (S3):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 20% fat component, 18% protein component, 60% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 63% of diglyceride and 37% of nutrition oil, the nutrition oil consists of 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil, the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin and beta-glucan in the carbohydrate is 10:1.
Example 4 (S4):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 15% fat component, 15% protein component, 68% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 63% of diglyceride and 37% of nutrition oil, the nutrition oil consists of 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil, the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin and beta-glucan in the carbohydrate is 10:1.
Example 5 (S5):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 13% fat component, 25% protein component, 60% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 63% of diglyceride and 37% of nutrition oil, the nutrition oil consists of 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil, the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin and beta-glucan in the carbohydrate is 10:1.
Example 6 (S6):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 13% fat component, 15% protein component, 70% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 63% of diglyceride and 37% of nutrition oil, the nutrition oil consists of 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil, the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin and beta-glucan in the carbohydrate is 10:1.
Example 7 (S7):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 15% fat component, 20% protein component, 63% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 60% of diglyceride and 40% of nutrition oil, the nutrition oil consists of 10% of perilla seed oil, 10% of peony seed oil, 10% of walnut oil, 6% of sea buckthorn oil and 4% of DHA algae oil, the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin and beta-glucan in the carbohydrate is 10:1.
Example 8 (S8):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 15% fat component, 20% protein component, 63% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 70% of diglyceride and 30% of nutrition oil, the nutrition oil consists of 10% of perilla seed oil, 8% of peony seed oil, 8% of walnut oil, 3% of sea buckthorn oil and 1% of DHA algae oil, the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin and beta-glucan in the carbohydrate is 10:1.
Example 9 (S9):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 15% fat component, 20% protein component, 63% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 50% of diglyceride and 50% of nutrition oil, the nutrition oil consists of 15% of perilla seed oil, 12% of peony seed oil, 12% of walnut oil, 7% of sea buckthorn oil and 4% of DHA algae oil, the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin and beta-glucan in the carbohydrate is 10:1.
Comparative example 1 (D1):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 40% fat component, 20% protein component, 38% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 63% of diglyceride and 37% of nutrition oil, the nutrition oil consists of 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil, the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin and beta-glucan in the carbohydrate is 10:1.
Comparative example 2 (D2):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 5% fat component, 25% protein component, 68% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 63% of diglyceride and 37% of nutrition oil, the nutrition oil consists of 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil, the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin and beta-glucan in the carbohydrate is 10:1.
Comparative example 3 (D3):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 10% fat component, 35% protein component, 53% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 63% of diglyceride and 37% of nutrition oil, the nutrition oil consists of 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil, the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin and beta-glucan in the carbohydrate is 10:1.
Comparative example 4 (D4):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 20% fat component, 10% protein component, 68% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 63% of diglyceride and 37% of nutrition oil, the nutrition oil consists of 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil, the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin and beta-glucan in the carbohydrate is 10:1.
Comparative example 5 (D5):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 10% fat component, 8% protein component, 80% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 63% of diglyceride and 37% of nutrition oil, the nutrition oil consists of 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil, the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin and beta-glucan in the carbohydrate is 10:1.
Comparative example 6 (D6):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 20% fat component, 28% protein component, 50% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 63% of diglyceride and 37% of nutrition oil, the nutrition oil consists of 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil, the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin and beta-glucan in the carbohydrate is 10:1.
Comparative example 7 (D7):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 5% fat component, 15% protein component, 78% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 63% of diglyceride and 37% of nutrition oil, the nutrition oil consists of 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil, the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin and beta-glucan in the carbohydrate is 10:1.
Comparative example 8 (D8):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 40% fat component, 35% protein component, 23% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 63% of diglyceride and 37% of nutrition oil, the nutrition oil consists of 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil, the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin and beta-glucan in the carbohydrate is 10:1.
Comparative example 9 (D9):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 15% fat component, 20% protein component, 63% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 30% of diglyceride and 70% of nutrition oil, the nutrition oil consists of 35% of perilla seed oil, 32% of peony seed oil and 3% of DHA algae oil, the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin and beta-glucan in the carbohydrate is 10:1.
Comparative example 10 (D10):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 15% fat component, 20% protein component, 63% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 30% of diglyceride and 70% of nutrition oil, the nutrition oil consists of 35% of walnut oil, 32% of sea buckthorn oil and 3% of DHA algae oil, the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin and beta-glucan in the carbohydrate is 10:1.
Comparative example 11 (D11):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 15% fat component, 20% protein component, 63% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 30% of perilla seed oil, 30% of peony seed oil, 20% of walnut oil, 10% of sea buckthorn oil and 10% of DHA algae oil, the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin and beta-glucan in the carbohydrate is 10:1.
Comparative example 12 (D12):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 15% fat component, 20% protein component, 63% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 40% of perilla seed oil, 40% of peony seed oil and 20% of DHA algae oil, the mass ratio of buckwheat protein to phycocyanin to whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin to beta-glucan in the carbohydrate is 10:1.
Comparative example 13 (D13):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 15% fat component, 20% protein component, 63% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 40% of walnut oil, 40% of sea buckthorn oil and 20% of DHA algae oil, the mass ratio of buckwheat protein to phycocyanin to whey protein in the protein component is 1:1:2, and the mass ratio of maltodextrin to beta-glucan in the carbohydrate is 10:1.
Comparative example 14 (D14):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 15% fat component, 20% protein component, 63% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 63% of diglyceride and 37% of nutrient oil, the nutrient oil consists of 20% of perilla seed oil, 5% of peony seed oil, 5% of walnut oil, 2% of sea buckthorn oil and 5% of DHA algae oil, and the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2; the mass ratio of maltodextrin to beta-glucan in the carbohydrate is 10:1.
Comparative example 15 (D15):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 15% fat component, 20% protein component, 63% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 40% of diglyceride and 60% of nutrition oil, the nutrition oil consists of 15% of perilla seed oil, 12% of peony seed oil, 20% of walnut oil, 10% of sea buckthorn oil and 3% of DHA algae oil, and the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2; the mass ratio of maltodextrin to beta-glucan in the carbohydrate is 10:1.
Comparative example 16 (D16):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 15% fat component, 20% protein component, 63% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; wherein the fat component consists of 80% of diglyceride and 20% of nutrition oil, the nutrition oil consists of 5% of perilla seed oil, 3% of peony seed oil, 8% of walnut oil, 3% of sea buckthorn oil and 1% of DHA algae oil, and the mass ratio of buckwheat protein, phycocyanin and whey protein in the protein component is 1:1:2; the mass ratio of maltodextrin to beta-glucan in the carbohydrate is 10:1.
Comparative example 17 (D17):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 15% fat component, 20% protein component, 63% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; the fat component consists of 63% of diglyceride and 37% of nutrient oil, wherein the nutrient oil consists of 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil; the mass ratio of the buckwheat protein to the phycocyanin in the protein component is 2:1; the mass ratio of maltodextrin to beta-glucan in the carbohydrate is 10:1.
Comparative example 18 (D18):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 15% fat component, 20% protein component, 63% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; the fat component consists of 63% of diglyceride and 37% of nutrient oil, wherein the nutrient oil consists of 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil; the mass ratio of the buckwheat protein, the phycocyanin and the whey protein in the protein component is 2:1:1; the mass ratio of maltodextrin to beta-glucan in the carbohydrate is 10:1.
Comparative example 19 (D19):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 15% fat component, 20% protein component, 63% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; the fat component consists of 63% of diglyceride and 37% of nutrient oil, wherein the nutrient oil consists of 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil; the mass ratio of the buckwheat protein, the phycocyanin and the whey protein in the protein component is 3:2:1; the mass ratio of maltodextrin to beta-glucan in the carbohydrate is 10:1.
Comparative example 20 (D20):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 15% fat component, 20% protein component, 63% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; the fat component consists of 63% of diglyceride and 37% of nutrient oil, wherein the nutrient oil consists of 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil; the mass ratio of the buckwheat protein, the phycocyanin and the whey protein in the protein component is 1:1:1; the mass ratio of maltodextrin to beta-glucan in the carbohydrate is 10:1.
Comparative example 21 (D21):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 15% of fat components, 20% of protein components, 63% of carbohydrate components, 0.8% of compound vitamins and 1.2% of compound minerals, wherein the fat components consist of 63% of diglycerides and 37% of nutritional oils, and the nutritional oils consist of 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil; the protein component consists of buckwheat protein; the mass ratio of maltodextrin to beta-glucan in the carbohydrate is 10:1.
Comparative example 22 (D22):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 15% fat component, 20% protein component, 63% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; the fat component consists of 63% of diglyceride and 37% of nutrient oil, wherein the nutrient oil consists of 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil; the mass ratio of the buckwheat protein, the phycocyanin and the whey protein in the protein component is 1:1:2; the mass ratio of maltodextrin to beta-glucan in the carbohydrate is 1:10.
Comparative example 23 (D23):
a total nutrient formula food suitable for special medical use of pancreatitis patients comprises the following raw materials in percentage by weight: 15% fat component, 20% protein component, 63% carbohydrate component, 0.8% complex vitamin, 1.2% complex mineral; the fat component consists of 63% of diglyceride and 37% of nutrient oil, wherein the nutrient oil consists of 12% of perilla seed oil, 9% of peony seed oil, 8% of walnut oil, 5% of sea buckthorn oil and 3% of DHA algae oil; the mass ratio of the buckwheat protein, the phycocyanin and the whey protein in the protein component is 1:1:2; the carbohydrate consists of maltodextrin.
The specific formulation compositions of the above examples and comparative examples are shown in Table 1.
Table 1 specific formulation composition (%)
/>
/>
Note that: in the above embodiments and comparative examples, the composition ratios of the protein component and the carbohydrate component are not specifically described, and are all compounded according to the optimal ratio; wherein, in the optimal scheme, the mass ratio of the buckwheat protein to the phycocyanin to the whey protein is 1:1:2; the mass ratio of maltodextrin to beta-glucan is 10:1.
Test example 1:
fatty acid composition determination of fat component: the fatty acid composition analysis was carried out with reference to "determination of fatty acid in national food safety Standard of food" GB 5009.168-2016. Determination of lipid accompaniments (polyphenols, phytosterols, tocopherols, squalene, etc.) in the fat module: lipid concomitants (polyphenols, phytosterols, tocopherols, squalene, etc.) were measured using high performance liquid chromatography.
The results are shown in tables 2 and 3.
Table 2 fatty acid composition (%)
/>
TABLE 3 lipid companion content (mg/kg) for each of the examples and comparative examples
As can be seen from Table 2, examples 1-9 are rich in diglycerides and each fatty acid has a reasonable composition, and the diglycerides account for 50-70% of the fat component, so that not only can the HTG-AP patients be provided with sufficient energy requirements, but also the effects of reducing blood fat can be achieved. Meanwhile, the essential fatty acid alpha-linolenic acid, the functional fatty acid eicosapentaenoic acid and the docosahexaenoic acid are also added in the groups of the examples 1 to 9, so that the problem of the lack of the essential fatty acid caused by only taking the diglyceride is solved. Table 3 also shows the lipid companion compositions included in each of the examples and comparative examples, wherein the groups of examples 1-9 are enriched in tocopherols, sterols and beta-carotene.
Test example 2:
animal experiment: normal male Wistar rats were placed in a rat cage and maintained in a simulated environment with light circulation for 12 hours at constant temperature (24±2) °c and relative humidity (50±5)%. The experimental rats were randomly divided into control group (CON), model group (model MOD) and 9 according to body weight after 7d of adaptationExample group, 23 comparative example groups. At the initial stage of the experiment, the rats of each group except the rats of the control group were fed with the high fat diet for 4 weeks to induce the hyperlipidemia model. During this period, it was judged whether the model was successful or not based on the concentrations of TG and TC in the rat serum (model establishment was successful when the contents of TG and TC in each group increased to 2 to 3 times that in the control group). Rana extract (50 mug.kg) -1 ) Once per hour, 8 consecutive injections induced an acute pancreatitis model (HTG-AP model).
(molecules,2022,27,2783.https://doi.org/10.3390/molecules27092783)
Serum analysis:
portal vein blood collection, 4000 Xg (4 ℃ C., 20 min) centrifugation. Serum was collected, and sub-packaged with sterile pipette, one part was used to determine serum lipase and amylase, and the other part was stored at-80 ℃ for analysis. Serum samples were equilibrated at 4℃for 10 min and then analyzed for Amylase (AMLY) and Lipase (LIPA) levels using a Vet Test 8008 automated biochemical analyzer (IDEXX BioInd. Co., westbrook, ME, USA, USA). Results are expressed in International units per liter (U/L). Serum was thawed at-80℃and analyzed for relevant indicators. Tumor necrosis factor-alpha (TNF-alpha), interleukin-10 (IL-10), interleukin-6 (IL-6), and detection kits were provided by Kavin biotechnology Co., ltd. Triglycerides (TG), total Cholesterol (TC) and detection kits were purchased from the institute of bioengineering, south kyo.
The results are shown in Table 4. Comprises the following blood fat detection indexes: total Cholesterol (TC), triglycerides (TG); inflammation level: TNF-alpha, IL-6 and IL-10 (anti-inflammatory factor);
common indicators of pancreatic function (digestive metabolic parameters) were tested: serum Amylase (AMLY), serum Lipase (LIPA).
Table 4 serum analysis results of examples and comparative examples
/>
Serum triglyceride, cholesterol, amylase and lipase concentrations are common indicators for detecting HTG-AP levels. Rat serum analysis is shown in table 4. After induction of the hyperlipidemic acute pancreatitis model, TC, TG, AMLY, LIPA content in the serum of the model-building mice was significantly increased (p < 0.05) compared to the control group, indicating successful induction of the model-building HTG-AP model. As can be seen from table 4, in the groups of examples 1 to 9, the TC, TG, AMLY, LIPA level in the serum of the mice was significantly reduced (p < 0.05) as compared with the model group, and in the groups of comparative examples 1 to 23, the TC, TG, AMLY, LIPA level was slightly reduced as compared with the model group, but the reduction was not as large as in the group of examples, and the respective composition ranges in the examples were more reasonable and effective. Among them, the TC, TG, AMLY, LIPA level of example 1 was most reduced, closest to the control, and the improvement was the best, while the comparative examples 11 to 13 were not significantly changed after the intervention, and the improvement was the worst.
The onset of acute pancreatitis and hyperlipidemia induces the release of pro-inflammatory cytokines such as IL-6, TNF-alpha, etc. from pancreatic acinar cells, which trigger multiple organ dysfunction or exacerbation of systemic inflammatory response syndrome by activating nuclear transcription factor NF- κB to produce a large amount of inflammatory mediators. Thus, the course of HTG-AP and the extent of inflammatory development can be analyzed based on the concentration of inflammatory factors, where IL-6, tnf- α is a pro-inflammatory factor and IL-10 is an anti-inflammatory factor. The inflammatory cell secretion level was measured in each group of mice, and the results are shown in Table 4. The serum proinflammatory factor level of the mice in the membranous group is obviously higher than that of the control group (p < 0.05), and the proinflammatory factor level is obviously lower than that of the control group (p < 0.05). After dry prognosis, serum IL-6, TNF- α levels were significantly reduced and IL-10 levels were significantly increased in the groups of examples 1-9 compared to the membranous group, while the serum IL-6, TNF- α levels were significantly reduced and IL-10 levels were significantly increased in the groups of comparative examples 1-23 compared to the group of examples (p < 0.05). Wherein, the TIL-6, TNF-alpha and IL-10 level increase levels of the example 1 group are the largest, which is closest to the control group, and the improvement effect is the best, while the comparison examples 11-13 groups have no obvious change after intervention, and the improvement effect is the worst.
Pancreatic tissue edema: the extent of pancreatic edema was assessed by the ratio of the mass lost after pancreas drying to the wet weight of the pancreas.
The results are shown in Table 5.
Table 5 ratio of pancreatic edema levels for each of the examples and comparative examples
/>
The extent of pancreatic organ edema can directly reflect the severity of rat pancreatic injury and HTG-AP. As shown in Table 5, the wet/dry mass ratio of the pancreas of the model building block was significantly higher than that of the control, indicating that the pancreas of the model building block was damaged and significantly edematous. In the dry state, the ratio of the degree of pancreatic edema was decreased in each of the groups of examples 1 to 9 as compared with the model group, and the ratio of the degree of pancreatic edema was higher in each of the groups of comparative examples 1 to 23 as compared with any of the groups of examples. Wherein, the group of the example 1 is reduced by about 29.76% compared with the molding group, and the group of the comparative examples 11-13 is reduced by about 0.49% compared with the molding group, and the change is almost no obvious.
In summary, the group of examples 1 to 9 had better improvement effects than the comparative examples, with the group of example 1 promoting the improvement of HTG-AP effect being most pronounced.
The above examples are not intended to limit the scope of the invention nor the order of execution of the steps described. The present invention is obviously modified by a person skilled in the art in combination with the prior common general knowledge, and falls within the scope of protection defined by the claims of the present invention.
Claims (10)
1. The total nutrient formula food for special medical use for pancreatitis patients is characterized by comprising, by mass, 10% -20% of fat components, 15% -25% of protein components, 60% -70% of carbohydrate components, 0.5% -1% of compound vitamins and 1% -5% of compound minerals; wherein: the fat component consists of diglyceride and nutritional oil.
2. A total nutrient formula for special medical use in pancreatitis patients according to claim 1, characterized in that the protein module consists of buckwheat protein, phycocyanin, whey protein; the carbohydrate consists of maltodextrin and beta-glucan.
3. A total nutrient formula for special medical use in pancreatitis patients according to claim 1, characterized in that the fat component is present in the total nutrient formula in an amount of 10%, 13%, 15%, or 20%.
4. A total nutrient formulation suitable for use in particular medicine for pancreatitis patients according to claim 1, wherein the protein component is present in the total nutrient formulation in an amount of 15%, 18%, 20%, 23%, or 25%.
5. A total nutritional formula for special medical use in patients with pancreatitis according to claim 1, characterized in that the carbohydrate component is present in the total nutritional formula in an amount of 60%, 63%, 65%, 68%, or 70%.
6. The total nutrient formula for special medical use for pancreatitis patients according to claim 1, wherein the fat component, protein component, carbohydrate component, compound vitamin, compound mineral, and the total nutrient formula are 15%, 20%, 63%, 0.8%, and 1.2% by mass, respectively.
7. A total nutrient formula for special medical use in pancreatitis patients according to claim 1, characterized in that the fat component comprises, in mass percent, 50-70% diglycerides, and the nutrient oil is supplemented to 100%.
8. The total nutrient formula food for special medical use for pancreatitis patients according to claim 1, wherein the fat component comprises, in mass percent, 50-70% of diglyceride, 10-15% of perilla seed oil, 8-12% of peony seed oil, 8-12% of walnut oil, 3-7% of sea buckthorn oil and 1-4% of DHA algae oil.
9. The total nutrient formula for special medical use for pancreatitis patients according to claim 1, characterized in that the mass ratio of buckwheat protein, phycocyanin, whey protein in the protein module is 1:1-3:1-3; the mass ratio of maltodextrin to beta-glucan in the carbohydrate component is (8-12): 1.
10. a total nutrient formulation suitable for use in particular medicine for patients with pancreatitis according to any of claims 1 to 9, characterized in that said pancreatitis is hyperlipidemia pancreatitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310823274.XA CN116918963A (en) | 2023-07-06 | 2023-07-06 | Total nutrient formula food applicable to pancreatitis patients and having special medical application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310823274.XA CN116918963A (en) | 2023-07-06 | 2023-07-06 | Total nutrient formula food applicable to pancreatitis patients and having special medical application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116918963A true CN116918963A (en) | 2023-10-24 |
Family
ID=88378285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310823274.XA Pending CN116918963A (en) | 2023-07-06 | 2023-07-06 | Total nutrient formula food applicable to pancreatitis patients and having special medical application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116918963A (en) |
-
2023
- 2023-07-06 CN CN202310823274.XA patent/CN116918963A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100678831B1 (en) | Phytosterol and/or phytostanol derivatives | |
| KR101362989B1 (en) | Lipid-improving agent and composition containing lipid-improving agent | |
| Yue et al. | Medium-, long-and medium-chain-type structured lipids ameliorate high-fat diet-induced atherosclerosis by regulating inflammation, adipogenesis, and gut microbiota in ApoE−/− mice | |
| Choopani et al. | Spirulina: a source of gamma-linoleic acid and its applications | |
| WO2004052115A1 (en) | Glyceride compositions and methods of making and using same | |
| Go et al. | Effects of microalgal polyunsaturated fatty acid oil on body weight and lipid accumulation in the liver of C57BL/6 mice fed a high fat diet | |
| CN109965031B (en) | Formula of fat component of formula food for special medical application for inflammatory bowel diseases and preparation method | |
| CN103380826A (en) | Functional fat with cardiovascular and cerebrovascular disease risk factor prevention function and preparation method thereof | |
| Fotschki et al. | Dietary supplementation with raspberry seed oil modulates liver functions, inflammatory state, and lipid metabolism in rats | |
| WO2020244315A1 (en) | Glyceride mixture rich in polyunsaturated fatty acids, preparation method therefor and application thereof | |
| CN113287659A (en) | Functional structural oil and preparation method and application thereof | |
| Ding et al. | Effects of phytosterol supplementation on growth performance, serum lipid, proinflammatory cytokines, intestinal morphology, and meat quality of white feather broilers | |
| He et al. | Plasma triacylglycerol-reducing activity of ergosterol linolenate is associated with inhibition of intestinal lipid absorption | |
| CN105341184A (en) | Functional fat composition having effects of preventing cardiovascular and cerebrovascular diseases and diabetes risk factors | |
| CN116918963A (en) | Total nutrient formula food applicable to pancreatitis patients and having special medical application | |
| Maekivuokko et al. | The effect of cocoa and polydextrose on bacterial fermentation in gastrointestinal tract simulations | |
| JP5259832B2 (en) | Conjugated linoleic acid-containing aqueous nanoemulsion composition | |
| CN109805108B (en) | Special medical application formula food fat component for inflammatory bowel diseases and preparation method thereof | |
| CN110150666B (en) | Grease composition and preparation method thereof | |
| CN117814321B (en) | Composite grease of chlamydomonas reinhardtii oil and corn diglyceride oil and preparation process thereof | |
| CN114009786B (en) | Nutritional oil composition for vitamin D delivery, preparation method and application | |
| CN1618303A (en) | Health-care oil for preventing cardiovascular and cerebrovascular disease | |
| CN115005287B (en) | Formula food fat component suitable for special medical use for diabetics | |
| CN117694408A (en) | Edible plant blend oil capable of reducing hyperlipidemia | |
| CN116019149B (en) | Formula food fat component with special medical application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |